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Abstract: This is a review of the literature concerning the 
interesting properties of p-, d-, and f-block elements when 
coordinated with 2,6-pyridinedicarboxylic acid (dipicolinic 
acid, H2dipic) and its derivatives as ligands, with a focus on 
their use as inorganic pharmaceuticals. Some of the com-
plexes reported were used as insulin-like, bioimaging con-
trasting agents, antimicrobial agents, and anticancer agents.
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Introduction
The review focuses on the interesting properties of p-, d-, 
and f-block elements when coordinated with 2,6-pyridine-
dicarboxylic acid (dipicolinic acid, H2dipic) and its deriv-
atives as ligands, with a focus on their use as inorganic 
pharmaceuticals. 2,6-Pyridinedicarboxylic acid (dipico-
linic acid, H2dipic), I, is a widely used building block in 
coordination and supramolecular chemistry (Froidevaux 
et al. 2000, Muller et al. 2001, Hunag et al. 2003, Storm and 
Luning 2003, Haino et al. 2005). It is a versatile, strong, 
nitrogen-oxygen, multimodal donor ligand, which forms 
stable complexes with diverse metal ions, sometimes in 
unusual oxidation states (Renaud et al. 1997a,b, Jackson 
et al. 2001, Devereux et al. 2002, Ouali et al. 2002, Kapoor 





The crystal structure of dipicolinic acid was first solved 
by Takusagawa et  al. (1973). Lately, the pharmacological 
studies on dipicolinic acid have been given pertinent atten-
tion because of its low toxicity and amphophilic nature. 
Dipicolinic acid is also present in natural systems as a 
product of oxidative degradation of vitamins, coenzymes, 
and alkaloids, to name a few (Siddiqi et al. 2010). Further-
more, it is constituent of fulvic acid, and is an intermediate 
during l-tryptophan degradation as well as a precursor for 
the NAD enzyme (Siddiqi et al. 2010). Dipicolinic acid and 
its derivatives are now being featured as ligands in coor-
dination complexes that have medicinal uses. The readers 
are encouraged to read reviews and articles for informa-
tion regarding the solution chemistry of dipicolinic acid, 
its derivatives, and its coordination complexes (Buglyo 
et al. 2005, Smee et al. 2009, Kirillov and Shul’pin 2013). 
Please see the following review “Pyrazinecarboxylic acid 
and analogs: Highly efficient co-catalysts in the metal-
complex-catalysed oxidation of organic compounds” 
(Kirillov and Shul’pin 2013). In this report, the reviews and 
featured articles have been published on the following 
topics: antidiabetic effects of a series of vanadium dipico-
linate complexes in rats with streptozotocin (STZ)-induced 
diabetes (Willsky et  al. 2011); how environment affects 
drug activity: localization, compartmentalization, and 
reactions of a vanadium insulin-enhancing compound, 
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dipicolinatooxidovanadium(V) (Crans et  al. 2011); and 
metal speciation in health and medicine represented by 
iron and vanadium (Crans et al. 2013).
Titanium
The chelate stabilization of a titanium(IV) (TiIV)-salan 
alkoxide by ligand exchange with dipicolinic acid was 
reported to form the redox inactive, heptacoordinate 
complex 1. This was found to be stable in both silica gel 
and aqueous media (Immel et al. 2012). The complex was 
reported to be highly toxic toward cervix carcinoma, HeLa 
S3, hepatocarcinoma, and Hep G2 cancer cell lines. It was 
also found to have an enhanced antitumor efficacy in a 












The relative efficacy of complex 1 was compared to 
another derivative in an in vivo model of cervical cancer; 
18 C3 tumor-bearing mice received the complexes in a low-
dose regime over multiple applications and their relative 
tumor inhibitory effects were monitored. Impressively, 
mice that were administered doses of complex 1 exhib-
ited a significant reduction in tumor size. These data were 
well received, although a reduction of tumor growth was 
previously reported using a high-dose treatment with TiIV 
halo-salan alkoxides. The dipic2- stabilized complex 1, in 
contrast to the TiIV halo-salan alkoxides, was well toler-
ated and showed an improved efficacy at lower doses 
(30 mg kg-1).
Vanadium
For many years, it has been reported that vanadium-con-
taining complexes have insulin-like properties both in vivo 
and in vitro. The synthesis and characterization of new 
vanadium complexes with insulin-like properties were 
reported (Crans et al. 2003a). The three new complexes were 
related to the (dipicolinato)dioxidovanadium(V) complex: 
(4-hydroxy-2,6-pyridinedicarboxylato)dioxido vanadium(V), 
(d iaqua)(4-hydroxy-2 ,6-pyr idinedicarbo xylato)
oxidovanadium(IV), and (4-amino- 2,6-pyridinedi-
carboxylato)dioxidovanadium(V). The complex (4-hydroxy- 
2,6-pyridinedicarboxylato)oxido vanadium(V) was 
investi gated in greater detail with regard to the chemistry, 
structure, kinetics, and insulin-like properties in rats with 
STZ-induced diabetes (Crans et al. 2003a). An oral adminis-
tration of [VO2(dipic-OH)]- was found to be effective in lower-
ing both the hyperglycemia and hyperlipidemia of diabetes. 
This was the first report concerning the effective lowering 
of diabetic hyperlipidemia by a vanadium(V) (VV) coordina-
tion complex (Crans et al. 2003a).
Recently, there was a report of a new insulin-like 
VV complex, the (4-hydroxypyridine-2,6-dicarboxylato)
oxovanadate(V) anion 2 (Crans et al. 2003b). The complex 
was designed based on the desire to make a compound 
with more favorable chemical and insulin-like proper-
ties than the analogous (pyridine-2,6-dicarboxylato)
oxovanadate(V) anion 3. The aqueous solution studies 
were carried out on complex 2, where the complex was 
found to be more stable at a neutral pH and had a dif-
ferent lability pattern than complex 3. The effect of 
complexes 2 and 3 anions on various biological systems 
including cell culture, yeast, and STZ-induced diabetic 
rats were investigated. The growth of myoblast cells (L6) 
was inhibited by both complexes 2 and 3 anions (Crans 
et al. 2003b). Since the complexes have limited stability 
at a neutral pH, yeast growth (pH range from 3.0 to 7.0) 
was employed as an adjunct cell model. The effect of the 
complex 3 anion on the inhibition of yeast cell growth 
was found to be pH dependent. The authors reported that 
these studies supported the hypothesis that the complex 
2 anion would be more active as an insulin-like agent 
because of its greater stability at a neutral pH (Crans 
et al. 2003b). The studies involving the effect of complex 
2 anion on hyperglycemia in rats with STZ-induced dia-
betes were also carried out. Complex 2 anion was found 
to lower the diabetic hyperglycemia and joined the ranks 
of the few VV complexes that have been shown to have 
insulin-like properties in a diabetic animal model system 
(Crans et al. 2003b).
The evaluation of the insulin-like character of a VV 
complex in STZ-induced diabetic rats was investigated. The 
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STZ-induced diabetic rats were orally administrated with 
sodium 4-amino-2,6-dipicolinatodioxidovanadium(V) 
dihydrate 4 (Li et  al. 2009). The complex was admin-
istered through an aqueous solution at a concentra-
tion of 0.1  mg ml-1 for 20 days; then, the concentration 
was increased to 0.3  mg ml-1 for the following 20 days. 
At the end of the studies, sodium complex 4 statisti-
cally significantly reduced the levels of blood glucose 
(p < 0.01), serum total cholesterol (p < 0.01), triglycerides 
(p < 0.01), and the activities of serum aspartate amino 
transferase (p < 0.05) and alkaline phosphatase (p < 0.01) 
compared to untreated diabetic animals (Li et  al. 2009). 
After treatment with 0.3  mg ml-1 sodium complex 4, the 
oral glucose tolerance was improved in diabetic animals 
(p < 0.01). In addition, the daily intake of elemental 
vanadium was markedly decreased in sodium 4-amino-
2,6-dipicolinatodioxidovanadium(V) dihydrate-treated 
diabetic rats compared to vanadyl sulfate-treated diabetic 
rats, which suggested that the antidiabetic activity of the 
element vanadium was elevated after being modified 
with the coordinated organic ligand (Li et al. 2009). These 
results suggested that sodium complex 4 was more effec-
tive than vanadyl sulfate at alleviating the symptoms of 
diabetes (Li et al. 2009).
The aqueous vanadium(III) (VIII) speciation chemis-
try of two dipicolinate-containing complexes (where the 
oxidation states of the vanadium metal center were +3, 
+4, and +5) and the insulin-like effects were carried out 
on a chronic animal model system (Buglyo et al. 2005). 
The characterization of the VIII species was carried out 
at a low ionic strength to reflect physiological condi-
tions. It required an evaluation of the hydrolysis of VIII 
at 0.20 m KCl. The aqueous VIII complexes with 2,6-pyri-
dinedicarboxylic acid (H2dipic) and 4-hydroxy-2,6-pyri-
dinedicarboxylic acid (H2dipic-OH) as ligands (where 
the complexes and their systems were designated as VIII-
dipic and VIII-dipic-OH) were characterized and the com-
plexes were observed from pH 2 to 7 at 0.2 M KCl (Buglyo 
et al. 2005). The VIII-dipic system formed stable 1:2 com-
plexes, whereas the VIII-dipic-OH system formed stable 
1:1 complexes. A comparison of these complexes with the 
V-pic system demonstrated that a second ligand has a 
lower affinity for the VIII species, presumably reflecting 
the bidentate coordination of the second dipic2- anion 
to the VIII species. The thermodynamic stability of the 
[VIII(dipic)2]- complex was compared to the stability of 
the corresponding vanadium(IV) (VIV) and VV complexes. 
Surprisingly, the VIII complexes were found to be more 
stable than anticipated (Buglyo et  al. 2005). An oral 
administration of H[VIII(dipic)2(H2O)]·3H2O 5, [VIVO(dipic)
(H2O)2]·2H2O, and NH4[VVO2(dipic)], along with the posi-
tive control, VOSO4, significantly lowered diabetic hyper-
glycemia in rats with STZ-induced diabetes (Buglyo et al. 
2005).
The STZ-induced diabetic rats treated with the VIII- 
and VIV-containing complexes had blood glucose levels 
that were statistically different from those of the diabetic 
group (Buglyo et al. 2005). The animals treated with the VV 
complex had the lowest blood glucose levels of the treated 
diabetic animals, which were statistically different from 
those of the diabetic group at all time points. Among the 
diabetic animals, the complexation to the dipicolinic acid 
ligand increased the serum levels of vanadium after the 
administration of the VV and VIV complexes but not after 
the administration of the VIII complex when data are nor-
malized to the ingested dose of vanadium (Buglyo et  al. 
2005). Due to the fact that the vanadium complexes with 
different oxidation states have different biological proper-
ties, it was implied that redox processes must be important 
factors for the biological action of vanadium-containing 
complexes. The authors of these studies observed that 
the VV complex was the most effective insulin-like agent, 
in contrast to previous studies in which the VIV complex 
with maltol as a ligand was the most effective. The authors 
concluded that the effectiveness of coordinated vanadium 
was both ligand and oxidation state dependent (Buglyo 
et al. 2005).
Three vanadium complexes of chlorodipicolinic acid 
(4-chloro-2,6-dipicolinic acid) in oxidation states (+3, +4, 
and +5) were prepared and their properties were char-
acterized across the various oxidation states. Addition-
ally, the series of hydroxylamido, methylhydroxylamido, 
dimethylhydroxylamido, and diethylhydroxylamido 
complexes were prepared from the chlorodipicolinato-
dioxidovanadium(V) complex (Smee et  al. 2009). The 
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chemical properties of the chlorodipicolinate com-
pounds are discussed and correlated with their insulin-
enhancing activity in STZ-induced diabetic Wistar rats 
(Smee et al. 2009). The effect of the chlorosubstitution on 
lowering diabetic hyperglycemia was evaluated and the 
differences were found depending on the compounds’ 
oxidation state, as was similarly observed for the vana-
dium-containing-dipicolinate complexes (Buglyo et  al. 
2005). However, a linear correlation of oxidation states 
with efficacy was not observed, which suggests that 
the differences in the mode of action are not simply an 
issue of redox equivalents. More importantly, the results 
obtained contrasted the previous observation with the 
vanadium-picolinate complexes, where the halogen sub-
stituents increased the insulin-enhancing properties of 
the complex (Takino et al. 2001).
Manganese
A manganese complex, [Mn(dipic)2]·6H2O 6, was tested 
for its antimicrobial activity (Tolga Çolak et al. 2009). In 
in vitro antibacterial and antifungal activities, the complex 
was tested with the use of the agar well diffusion method 
by minimal inhibition concentration (MIC) (Tolga Çolak 
et al. 2009). It was concluded that the complex was very 
effective against Gram-positive bacteria and fungi but 















The syntheses of Co(II) and Co(III) dipicolinate com-
plexes were reported via solid-state X-ray characteriza-
tion of [Co(H2dipic)(dipic)]·3H2O 7 and [Co(dipic)(μ-dipic)
Co(H2O)5]·2H2O 8, respectively, in which two new coordi-
nation modes were observed (Yang et al. 2002).  Solution 
studies show a high stability of the Co(III) complex, 
whereas the Co(II) complexes undergo pH-dependent 
ligand exchange in the presence of excess ligand (Yang 
et al. 2002). The [Co(dipic)2]2- anion was found to be effec-
tive in reducing the hyperlipidemia of diabetes using oral 
administered aqueous solutions to rats with STZ-induced 





























In another report by Azadbakht et  al., (H2dap)
[Co(dipic)2]·H2dipic·4H2O 9 (where dap = 3,4-diamino-
pyridine) was screened for its antimicrobial activities 
against Bacillus cereus (ATCC 11778), Bacillus subtilis 
(ATCC 12711), Staphylococcus aureus (ATCC 25923), Escher-
ichia coli (ATCC 25922), and Pseudomonas aeruginosa 
(ATCC 27853). However, the screening data revealed that 
compound 9 exhibited only inhibitory results against 
S. aureus (MIC  > 14  mg cm-3). This finding was of great 
interest because it seemed to show conflict toward the 
well-known antimicrobial characteristic of the pure dipic 
ligand toward a broad spectrum of bacteria (Chauvin et al. 
2006, Gaillard et al. 2013).
The confirmation of this observation was done via a 
comparison of independent data reported by Derikvand 
et al. (2012), Siddiqi et al. (2010), and Soleimani (2011). It 
is seen that the dipicolinic acid complexes show a varied 
resistance to bacterial growth. These data were further 
supported from the data retrieved from the antifungal 
studies of Siddiqi et  al. (2010) and also showed similar 
inhibitory results for the complexes containing dipicolinic 
acid as a ligand. It was therefore the general conclusion 
from these results that showed the overall structure of the 
tested compounds to be the principal factor influencing 
the antimicrobial activity.
Copper
Complexes 10 and 11 were tested for their ability to bind 
to DNA, and it was seen that there was π-π stacking 
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between the ligands of the complex and the base pairs 
of DNA (Tabatabaee et  al. 2013). A new Cu(II) complex, 
[Cu(Hdipic)(H2dipic)]OH-·2H2O 12, was tested for its anti-
microbial properties (Derikvand et  al. 2012). Complex 
12 was reported to have moderate inhibitory effects on 
B. subtilis, B. cereus, and S. aureus but had no effect on 













The ternary complex formation of some potent insulin-
like zinc(II) complexes of bidentate ligands, maltol and 
3-hydroxy-1,2-dimethyl-pyridinone with (O,O), 2-picolinic 
acid and 6-methylpicolinic acid with (N,O), and the tri-
dentate dipicolinic acid with (O,N,O) coordination modes, 
was studied in aqueous solutions by pH potentiometry 
and spectroscopic [UV-visible, circular dichroism (CD), 
and electrospray ionization-mass spectrometry (ESI-MS)] 
methods in the presence of critical cell constituents such 
as reduced l-glutathione (GSH) and adenosine 5′-triphos-
phate (ATP) (Enyedy et al. 2008). The results showed that 
the formation of the ternary complexes was hindered in 
the case of dipicolinic acid, especially with ATP, while it 
was favored with the bidentate ligands in the physiologi-
cal pH range (Enyedy et al. 2008). The driving force of the 
formation of mixed-ligand species was found to be a more 
enhanced coordination of GSH and ATP as second ligands 
in the ternary complexes than in their binary ones due to 
steric and electrostatic reasons. The mitochondrial dehy-
drogenase activity of the Zn(II) complexes, as an indirect 
indicator for the glucose intake, was measured on Mono 
Mac and 3T3-L1 adipocyte cell lines (Enyedy et al. 2008). 
The activity of the complexes up to ∼10–100 μm concentra-
tion was in the range of the effect of 0.75–1.5 μm insulin, 
while at higher concentration it was broken down due to 
the sensitivity of the cells and toxicity of the complexes 
(Enyedy et al. 2008).
Two ternary Zn(II) complexes with 1,10-phenan-
throline (phen) as the main ligand and a carboxylate-
containing ligand [dipicolinate (dipic2-) or l-threoninate 
(l-Thr)] as the subsidiary ligand were prepared and char-
acterized by elemental analysis, Fourier transform infra-
red (FTIR), UV-visible, fluorescence spectroscopy, X-ray 
diffraction, molar conductivity, and electrospray ioniza-
tion mass spectrometry (Chin et al. 2012). X-ray structure 
analysis showed that both [Zn(phen)(dipic)(H2O)]·H2O 
and [Zn(phen)(L-Thr)(H2O)Cl]·2H2O have octahedral 
geometry about the Zn(II) metal center. Both complexes 
were found to inhibit topoisomerase I and had better 
anticancer activity than cisplatin against nasopharyn-
geal cancer cell lines HK1 and HONE-1 with concentra-
tions causing 50% inhibition of cell proliferation (IC50 
values) in the low micromolar range (Chin et  al. 2012). 
The complex [Zn(phen)(l-Thr)(H2O)Cl]·2H2O had the 
highest therapeutic index for HK1 with a concentration 
of 1.3 μm. Both Zn(II) complexes were found to induce 
apoptosis. Changing the subsidiary ligand in the Zn(II) 
complexes affected the UV fluorescence spectral proper-
ties of the coordinated phen ligand, the binding affinity 
for some DNA sequences, nucleobase sequence selective 
binding, the phase at which cell cycle progression was 
arrested for treated cancer cells, and their therapeutic 
index (Chin et al. 2012).
Gallium
Two gallium(III) complexes (13 and 14) have been syn-
thesized with the first ligand being dipicolinic acid 
and the second being either 2-picolinic acid or phen 
(Kong and Sun 2009). The two gallium(III) complexes 
were reported to have antimicrobial activities against S. 
aureus, E. coli, and B. subtilis. The highest inhibitions 
were reported against S. aureus for both complexes 
when compared to the activity of the free ligands (Kong 
and Sun 2009).
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Ruthenium
Ruthenium(II)-arene complexes of general formulas 
[(η6-p-cymene)Ru(L1–3)Cl2] (where L1–3 = 3-acetylpyridine), 
4-acetylpyridine, and 2-amino-5-chloropyridine)), 
correspondingly, [(η6-p-cymene)Ru(HL4,5)Cl2] (where 
HL4 and HL5 are isonicotinic acid and nicotinic acid, 
respectively), and [(η6-p-cymene)Ru(HL6–9)Cl] (where 
H2L6–9 = 2,3-pyridinedicarboxylic acid, 2,4-pyridinedi-
carboxylic acid, 2,5-pyridinedicarboxylic acid, and 
2,6-pyridinedicarboxylic acid), were prepared by the 
reaction of [(η6-p-cymene)2RuCl2]2 with the correspond-
ing ligand in 1:2 molar ratio in isopropanol (Grguric-
Sipka et al. 2010). The complexes were characterized by 
elemental analysis, mass spectrometry, IR and nuclear 
magnetic resonance (NMR) spectroscopies, and X-ray 
crystallography, where appropriate (Grguric-Sipka et al. 
2010). The complexes revealed a low antiproliferative 
activity in six investigated tumor cell lines (HeLa, B16, 
FemX, MDA-MB-361, MDA-MB-453, and LS-174) (Grguric-
Sipka et al. 2010).
Rhodium
Several rhodium(II) complexes belonging to the general 
structure [Rh(CO)2(dipic-L)] [where L = dithiocarbamate 
(dtc) and xanthate derivatives] were synthesized and 
assayed as cytostatic and antitumor agents in vitro 
against KB cells and in vivo against P388 leukemia, 
Ehrlich ascites carcinoma, sarcoma 180 ascites, and 
ADJ/PC6A solid tumors. The assays against five Trypa-
nosoma strains were also performed. Among the new 
compounds, the [Rh(CO)2(dipic-dtc)] appeared to be 
active in all biological systems without showing evident 
nephrotoxicity (Sengupta et al. 1983, Craciunescu et al. 
1991).
Palladium
The palladium(II) complexes have been highly sought 
after in the realm of therapeutic anticancer drug devel-
opment because of the similarities in bioactivities 
and coordination behavior between palladium(II) and 
platinum(II) complexes. Although the principle mecha-
nism of its antitumor property is not yet known, it is con-
firmed that some species of the aromatic heterocycles can 
stack with nucleobases and then enhance the complex 
formation with DNA, which is the target in the chemo-
therapy of tumor. An example of such a heterocyclic 
complex is [Pd(phen)(Hdipic-)]·4H2O 15, as reported by 
Wang and Okabe (2005).
The interaction of [PdII(dipic)Cl]- with AMP, inosine-5′-
monophosphate (IMP), and reduced GSH was studied 
kinetically as a function of [L] (L = AMP, IMP, GSH) and [Cl-] 
and temperatures (10–35°C) at pH 4.0 (Chatterjee et  al. 
2005). It was seen that the [PdII(dipic)Cl]- anion complexes 
first go through aquation replacing the chloride ligand 
(Chatterjee et al. 2005). The aqua palladium(II) complexes 
were reported to bind to weak nucleophiles such as AMP 
and IMP (Chatterjee et al. 2005).
Tin
A series of diorganotin dipicolinates were synthesized 
and their antitumor activities against two human tumor 
cell lines MCF-7, a mammary tumor, and WiDr, a colon car-
cinoma, were determined (Gielen et al. 1991, Costa et al. 
2005). All complexes synthesized were only moderately 
active in both cell lines tested. Among the series of syn-
thesized complexes, n-Bu2Sn(2-O2C-C5H4N-3-OH)2 was the 
most active of the series (ID50 values = 96 and 337 ng ml-1 in 
MCF-7 and WiDr, respectively). All synthesized complexes 
showed less activity compared to similar previously syn-
thesized complexes, such as di-n-butyltin-bis(3-meth-
oxysalicylate), as characterized by ID50 values of 44 and 
82 ng ml-1 against MCF-7 and WiDr, respectively (Bouâlam 
et al. 1991).
Yttrium
The highly selective separation of yttrium and lanthanides 
is of interest for the design of radiopharmaceuticals for 
the treatment of illness such as cancer and rheumatism, 
Authenticated | masha.dorogova@degruyter.com
Download Date | 8/21/15 6:56 AM
M.J. Celestine et al.: Complexes of dipicolinic acid and its derivatives as medicine      63
and in the past decade, much interest has been taken 
in yttrium detection in biological applications (Horo-
vitz 1999, Okamoto and Fukuzumi 2004). Chauvin et  al. 
(2006) have demonstrated that imprinting a polymer with 
neutral [Y(16)3] [where 16 = 6-(4-vinylphenylcarbamoyl)
pyridine-2-carboxylic acid] complexes, followed by acid 
demetallation, leads to resins highly selective for YIII and 
heavy LnIII ions (Chauvin et al. 2006). The obtained ion-
imprinting effect stems from the rigid geometry imposed 
by the three dipicolinate-based ligand strands, which are 
maintained upon polymerization with styrene and divi-
nylbenzene. The ion-imprinted polymer based on complex 
16 was particularly efficient at extracting yttrium and has 
a sizeable capacity (8.9 ± 0.2  mg g-1 resin) and a fast rate 
of extraction (t1/2 = 1.7 min) (Chauvin et al. 2006). Complex 
16 showed high selectivity for yttrium and lanthanide 
cations when compared against alkali and alkaline earth 
metals opening the potential for its use in the production 
of highly pure 90Y and radiolanthanides for medicinal 
application and for the trace analysis of radiochemicals in 
food and the environment.
Lanthanides
Gaillard et  al. (2013) have recently developed a “click” 
approach to synthesize dipicolinic acid derivatives for 
lanthanide chelates, which take advantage of the intrinsic 
efficiency of the copper-catalyzed azide-alkyne cycload-
dition (CuAAC) reaction. The simple dipicolinic acid 
Na3Eu(17)3 and Na3Tb(17)3 complexes were used for the 
comparison for Eu3+ and Tb3+ 4-triazolyl-DPA complexes 
against Na3Eu(18)3, Na3Tb(18)3, Eu(19)3, Tb(19)3, Eu(20)3, 
and Tb(20)3 bearing a hydroxymethyl, a chlorine, and a 
trimethyl ammonium appendage, respectively. These 
4-triazolyl-DPAs have shown promising results under 
two-photon excitation (TPE) and three-photon excitation 
(THPE). The nanoparticles containing the lanthanide 
complexes were obtained by a classic reverse emulsion 
process involving tetraethyl orthosilicate (TEOS), NP-5 
surfactant [polyoxyethylene (5) nonylphenyl ether], and 
ammonia. The photophysical properties of NP-(17)3 to 
NP-(20)3 showed two distinguishable types of NPs. No 
significant luminescence was observed for NP-(17)3 and 
NP-(18)3, indicating a poor incorporation of the rare-
earth complexes into the silica matrix. Conversely, the 
complexes bearing the ammonium moieties [NP-Eu(19)3, 
NP-Tb(19)3, and NP-Eu(20)3] were more easily embedded 
into the silica nanoparticles, owning to their enhanced 
capability to interact with the silica network, due to the 
interactions between the ammonium moieties and the 
deprotonated silanol groups. The treatment of NP-Eu(19)3-
NH2 with an excess of homobifunctional polyethylene 
glycol (PEG) yielded luminescent PEGylated NPs NP-
Eu(19)3-PEG-NHS. The presence of the -NHS termini on 
the NP’s surface allows for the bioconjugation of these 
nano-objects with biomolecules, potentially leading to 
the applications of specified biolabeling and bioimaging 
(Gaillard et al. 2013).
The functionalized tris-dipicolinate europium(III) com-
plexes have been reported to show two-photon absorption 
but exhibit weak stability in aqueous solutions due to the 
ligand substitution by water molecules, which radically 
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decreases the luminescence quantum yield and lifetime of 
the complexes (Chauvin et al. 2004, Picot et al. 2008).
2H o3- - 2-
3 2 2 x[ Ln( DPA) ] [ Ln( DPA) ( H O) ] DPA+⇀↽
Tris-dipicolinate europium complexes [Eu(dipic)3]3- 
(21) where the dipicolinic acid was functionalized by 
donor-π-conjugated moieties (Kong and Sun 2009, Grgu-
ric-Sipka et al. 2010), and further decorated with hydro-
solubilizing PEG end-groups (22), were synthesized by 
Picot et  al. (2008). These novel europium complexes 
fulfilled all of the requirements for use in biomedical 
imaging application: (i) water solubility, (ii) intense emis-
sion, (iii) long luminescence lifetime, and (iv) significant 
two-photon absorption. Philippot et  al. (2011) utilized a 
one-step method based on the spray drying of sol-gel solu-
tions involving silicon alkoides as precursors of silica NPs 
to incorporate and further stabilize similar lanthanide 
complexes in aqueous media. The best water dispersion 
and chemical stability of the Eu complexes embedded 
in silica NPs were obtained using an 8TMOS+1BTTPOHD 
silica matrix composition [where TMOS = tetramethoxysi-
lane and BTTPOHD = 1,16-bis(trimethoxysilyl)-4,7,10,13-
tetraoxahexadecane]. Luminescence lifetimes remained 
constant upon dilution and similar values were obtained 
to those measured in the solid state, confirming the pres-
ence of nondissociated Eu complexes. High luminescent 
intensity and good photostability were registered for NPs 
slightly doped with Eu complexes (5 wt.%) by two-pho-
ton microscopy. The BTTPOHD moiety contained a PEG 
moiety further increasing the biocompatibility of these 
doped NPs, thus increasing the possibility of their poten-
tial application as stable biolabels for two-photon lumi-
nescence imaging (Philippot et al. 2011).
Platinum
Due to the success of cisplatin, there have been many 
studies conducted on its derivatives to enhance carci-
noma cell death while leaving the noncancerous cells 
intact (Chatterjee et  al. 2005). The complex [Pt(dipic)
Cl]- 23 was tested against breast (MCF-7), lung (NCI-
H460), and central nervous system (CNS) (SF-268) cancer 
cells where the inhibition toward all three cell lines was 
reported (Chatterjee et al. 2005). The growth inhibition of 
50% of the cell populations was perceived as 0.57, 0.50, 
and 0.70 mm for MCF-7, NCI-H460, and SF-268, respec-
tively (Chatterjee et al. 2005). The efficacy of complex 23 










The incorporation of the acidic Bi(III) ion with ligands 
bearing N-O donor atoms produced a wide selection of 
pharmaceutically active complexes (e.g., complex 24), 
which have been extensively used for the treatment 
of a broad spectrum of gastrointestinal disorders. The 
derivatives of dipicolinic acid have produced interesting 
motifs that exhibit relatively good stabilities in aqueous 
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environments and high solubilities in slightly acidic con-
ditions (Anjaneyulu et al. 2010, 2011).
Conclusion
In conclusion, the complexes with dipicolinic acid and its 
derivatives as ligands were reported to have effects that 
ranged from antibacterial and anticancer agents to having 
insulin-like properties. The different complexes were 
reported to have the ability to inhibit the growth of Gram-
positive bacteria and fungi, to cause apoptosis in cancer-
ous cells, to use as a bioimaging agent, or to reduce the 
blood glucose levels in STZ-induced diabetic rats.
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